Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1α-mediated apoptosis
Open accessAbstract
BACKGROUND: Clear cell renal cell carcinoma (CCRCC) is the commonest form of kidney cancer. Up to 91% have biallelic inactivation of VHL, resulting in stabilisation of HIF-α subunits. Factor inhibiting HIF-1 is an enzyme that hydroxylates HIF-α subunits and prevents recruitment of the co-activator CBP/P300. An important question is whether FIH-1 controls HIF activity in CCRCC. METHODS: Human VHL defective CCRCC lines RCC10, RCC4 and 786-O were used to determine the role of FIH-1 in modulating HIF activity, using small interfering RNA knockdown, retroviral gene expression, quantitative RT-PCR, western blot analysis, Annexin V and propidium iodide labelling. RESULTS: Although it was previously suggested that FIH-1 is suppressed in CCRCC, we found that FIH-1 mRNA and protein are actually present at similar levels in CCRCC and normal kidney. The FIH-1 inhibition or knockdown in the VHL defective CCRCC lines RCC10 and RCC4 (which express both HIF-1α and HIF-2α) resulted in increased expression of HIF target genes. In the 786-O CCRCC cell line, which expresses only HIF-2α, FIH-1 attenuation showed no significant effect on expression of these genes; introduction of HIF-1α resulted in sensitivity of HIF targets to FIH-1 knockdown. In RCC4 and RCC10, knockdown of FIH-1 increased apoptosis. Suppressing HIF-1α expression in RCC10 prevented FIH-1 knockdown from increasing apoptosis. CONCLUSION: Our results support a unifying model in which HIF-1α has a tumour suppressor action in CCRCC, held in check by FIH-1. Inhibiting FIH-1 in CCRCC could be used to bias the HIF response towards HIF-1α and decrease tumour cell viability.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HIF-1α is more sensitive to FIH-1-mediated inhibition than HIF-2α due to a specific amino acid difference between the two HIFs.
“Of note, HIF-1α is more sensitive to FIH-1-mediated inhibition than HIF-2α (Khan et al., 2011) due to a specific amino acid difference between the two HIFs (Bracken et al., 2006).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Khan et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · see citing works
Self-citationEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333 · see citing works
Self-citationDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712 · see citing works
Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558 · see citing works
Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550 · cited 1× · see citing works
“…asparagine residue (Asn 803 in human HIF-1a) within the C-terminal transactivation domain (CTAD) of HIF-a, thereby preventing binding of the co-factor p300 and inhibiting HIF transcriptional activation (Freedman et al, 2002; Hewitson et al, 2002; Lando et al, 2002a, b; Elkins et al, 2003).”
BackgroundRaval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940 · see citing works
Self-citationThe role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis: Figure 1
Greijer, A. E., & van der Wall, E. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.015032 · Cited by 781 · see citing works
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761 · see citing works
Hewitson, K. S., McNeill, L. A., Riordan, M. V., Tian, Y.-M., Bullock, A. N., Welford, R. W., Elkins, J. M., Oldham, N. J., Bhattacharya, S., Gleadle, J. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200273200 · Cited by 719 · see citing works
Sowter, H., Ratcliffe, P. J., Watson, P. H., Greenberg, A. H., & Harris, A. L. (2001) · PubMed · Cited by 711 · see citing works
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A. S., Gray, S. G., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 696 · see citing works
Wiesener, M. S., Turley, H., Allen, W. E., Willam, C., Eckardt, K., Talks, K., Wood, S. M., Gatter, K. C., Harris, A. L., Pugh, C. W., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2260 · Cited by 629 · see citing works
Self-citationInhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611 · see citing works
HIF activation identifies early lesions in VHL kidneys
Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00071-5 · Cited by 483 · see citing works
Self-citationStructural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α
Freedman, S. J., Sun, Z., Poy, F., Kung, A. L., Livingston, D. M., Wagner, G., & Eck, M. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082117899 · Cited by 457 · see citing works
Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00044-2 · Cited by 433 · see citing works
Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203938 · Cited by 396 · see citing works
Elkins, J. M., Hewitson, K. S., McNeill, L. A., Seibel, J. F., Schlemminger, I., Pugh, C. W., Ratcliffe, P. J., & Schofield, C. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200644200 · Cited by 391 · see citing works
Rankin, E. B., Tomaszewski, J. E., & Haase, V. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3241 · Cited by 356 · see citing works
Cockman, M. E., Lancaster, D. E., Stolze, I. P., Hewitson, K. S., McDonough, M. A., Coleman, M. L., Coles, C. H., Yu, X., Hay, R. T., Ley, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606877103 · Cited by 285 · see citing works
Zheng, X., Linke, S., Dias, J. M., Zheng, X., Gradin, K., Wallis, T. P., Hamilton, B. R., Gustafsson, M. V., Ruas, J. L., Wilkins, S. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711591105 · Cited by 271 · see citing works
Regulation of E-cadherin Expression by <i>VHL</i> and Hypoxia-Inducible Factor
Esteban, M. A., Tran, M. G. B., Harten, S. K., Hill, P., Castellanos, M. C., Chandra, A., Raval, R., O'Brien, T. S., & Maxwell, P. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2670 · Cited by 262 · see citing works
Self-citationThe Asparaginyl Hydroxylase Factor Inhibiting HIF-1α Is an Essential Regulator of Metabolism
Zhang, N., Fu, Z., Linke, S., Chicher, J., Gorman, J. J., Visk, D., Haddad, G. G., Poellinger, L., Peet, D. J., Powell, F. L., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.001 · Cited by 244 · see citing works
Coleman, M. L., McDonough, M. A., Hewitson, K. S., Coles, C., Mecinovicí, J., Edelmann, M., Cook, K. M., Cockman, M. E., Lancaster, D. E., Kessler, B. M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704102200 · Cited by 222 · see citing works
Bracken, C. P., Fedele, A. O., Linke, S., Balrak, W., Lisy, K., Whitelaw, M. L., & Peet, D. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600288200 · Cited by 222 · see citing works
(2000) · PubMed · Cited by 206 · see citing works
Yan, Q., Bartz, S., Mao, M., Li, L., & Kaelin, W. G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01514-06 · Cited by 193 · see citing works
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation
Frew, I. J., Thoma, C. R., Georgiev, S., Minola, A., Hitz, M., Montani, M., Moch, H., & Krek, W. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.96 · Cited by 156 · see citing works
Stolze, I. P., Tian, Y.-M., Appelhoff, R. J., Turley, H., Wykoff, C. C., Gleadle, J., & Ratcliffe, P. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406713200 · Cited by 155 · see citing works
Selective Inhibition of Factor Inhibiting Hypoxia-Inducible Factor
McDonough, M. A., McNeill, L. A., Tilliet, M., Papamicaël, C. A., Chen, Q., Banerji, B., Hewitson, K. S., & Schofield, C. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja050841b · Cited by 149 · see citing works
Two transactivation mechanisms cooperate for the bulk of HIF‐1‐responsive gene expression
Kasper, L. H., Boussouar, F., Boyd, K. L., Xu, W., Biesen, M. A., Rehg, J. E., Baudino, T. A., Cleveland, J. L., & Brindle, P. K. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600846 · Cited by 140 · see citing works
Cockman, M. E., Webb, J. D., Kramer, H., Kessler, B. M., & Ratcliffe, P. J. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800340-mcp200 · Cited by 139 · see citing works
To, K. K. W., & Huang, E. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504342200 · Cited by 105 · see citing works
Ferguson, J. E., Wu, Y., Smith, K. R., Charles, P. C., Powers, K. T., Wang, H., & Patterson, C. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00511-07 · Cited by 102 · see citing works
pVHL: A Multipurpose Adaptor Protein
Frew, I. J., & Krek, W. (2008) · Science Signaling · doi:10.1126/scisignal.124pe30 · Cited by 95 · see citing works
Lancaster, D. E., McNeill, L. A., McDonough, M. A., Aplin, R. T., Hewitson, K. S., Pugh, C. W., Ratcliffe, P. J., & Schofield, C. J. (2004) · Biochemical Journal · doi:10.1042/bj20040735 · Cited by 83 · see citing works
Morris, M. R., Maina, E. N., Morgan, N. V., Gentle, D., Astuti, D., Moch, H., Kishida, T., Yao, M., Schraml, P., Richards, F. M., et al. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.011767 · Cited by 69 · see citing works
Datta, K., Li, J., Bhattacharya, R., Gasparian, L., Wang, E., & Mukhopadhyay, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2706 · Cited by 64 · see citing works
Linehan, W. M., Rubin, J. S., & Bottaro, D. P. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.09.024 · Cited by 59 · see citing works
The inhibition of factor inhibiting hypoxia-inducible factor (FIH) by β-oxocarboxylic acids
Banerji, B., Conejo‐García, A., McNeill, L. A., McDonough, M. A., Buck, M. R., Hewitson, K. S., Oldham, N. J., & Schofield, C. J. (2005) · Chemical Communications · doi:10.1039/b510707e · Cited by 33 · see citing works
Linke, S., Hampton‐Smith, R. J., & Peet, D. J. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35004-0 · Cited by 29 · see citing works
Crystal Structures of Human FIH-1 in Complex with Quinol Family Inhibitors
Moon, H., Han, S., Park, H., & Choe, J. (2010) · Molecules and Cells · doi:10.1007/s10059-010-0058-3 · Cited by 18 · see citing works
Protein Kinase C-Mediated Modulation of FIH-1 Expression by the Homeodomain Protein CDP/Cut/Cux
Li, J., Wang, E., Dutta, S. K., Lau, J. S., Jiang, S., Datta, K., & Mukhopadhyay, D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02201-06 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687 · see citing works
“Of note, HIF-1α is more sensitive to FIH-1-mediated inhibition than HIF2α (Khan et al., 2011) due to a specific amino acid difference between the two HIFs (Bracken et al.”
BackgroundInfluentialHypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer
Schödel, J., Grampp, S., Maher, E. R., Moch, H., Ratcliffe, P. J., Russo, P., & Mole, D. R. (2015) · European Urology · doi:10.1016/j.eururo.2015.08.007 · Cited by 411 · see citing works
Wei, Y., Chen, X., Liang, C., Yan, L., Yang, X., Ye, X., Zhang, H., Yang, P., Cui, X., Ren, Y., et al. (2019) · Hepatology · doi:10.1002/hep.30795 · Cited by 244 · see citing works
Regulation of Tumor Progression by Programmed Necrosis
Lee, S. Y., Ju, M. K., Jeon, H. M., Jeong, E. K., Lee, Y. J., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3537471 · Cited by 225 · see citing works
Molecular targeting of hypoxia in radiotherapy
Rey, S., Schito, L., Koritzinsky, M., & Wouters, B. G. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.10.002 · Cited by 171 · see citing works
The Roles of Jumonji-Type Oxygenases in Human Disease
Johansson, C., Tumber, A., Che, K., Cain, P., Nowak, R. P., Gileadi, C., & Oppermann, U. C. T. (2014) · Epigenomics · doi:10.2217/epi.13.79 · Cited by 163 · see citing works
Repression of hypoxia-inducible factor α signaling by Set7-mediated methylation
Liu, X., Chen, Z., Xu, C., Leng, X., Cao, H., Ouyang, G., & Xiao, W. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv379 · Cited by 107 · see citing works
Novel Drugs with High Efficacy against Tumor Angiogenesis
Qi, S., Deng, S., Lian, Z., & Yu, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136934 · Cited by 88 · see citing works
Li, S., Chen, T., Zhong, Z., Wang, Y., Li, Y., & Zhao, X. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.779 · Cited by 82 · see citing works
Witvliet, D. K., Strokach, A. V., Giraldo-Forero, A. F., Teyra, J., Çolak, R., & Kim, P. M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw031 · Cited by 80 · see citing works
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
Pollard, P. J., Yang, M. H., Su, H., Soga, T., & Kranc, K. R. (2014) · Hypoxia · doi:10.2147/hp.s47968 · Cited by 65 · see citing works
Hypoxic regulation of the noncoding genome and NEAT1
Choudhry, H., & Mole, D. R. (2015) · Briefings in Functional Genomics · doi:10.1093/bfgp/elv050 · Cited by 59 · see citing works
Conde, E., Giménez-Moyano, S., Martín-Gómez, L., Rodríguez, M., Ramos, E., Aguado-Fraile, E., Blanco-Sánchez, I., Sáiz, A., & García‐Bermejo, L. (2017) · Scientific Reports · doi:10.1038/srep41099 · Cited by 55 · see citing works
Janke, K., Brockmeier, U., Kuhlmann, K., Eisenacher, M., Nolde, J., Meyer, H. E., Mairbäurl, H., & Metzen, E. (2013) · Journal of Cell Science · doi:10.1242/jcs.117564 · Cited by 52 · see citing works
Chen, Z., Liu, X., Mei, Z., Wang, Z., & Xiao, W. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00718-13 · Cited by 48 · see citing works
Cheung, C. C., Chung, G. T., Lun, S. W., To, K., Choy, K. W., Lau, K., Siu, S. P.-K., Guan, X., Ngan, R. K., Yip, T. T., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-184 · Cited by 46 · see citing works
Bacigalupa, Z. A., & Rathmell, W. K. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.034 · Cited by 45 · see citing works
The Asparagine Hydroxylase FIH: A Unique Oxygen Sensor
Volkova, Y. L., Pickel, C., Jucht, A. E., Wenger, R. H., & Scholz, C. C. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0003 · Cited by 42 · see citing works
Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma
Vícha, A., Taïeb, D., & Pacák, K. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0398 · Cited by 35 · see citing works
Wohlrab, C., Kuiper, C., Vissers, M. C. M., Phillips, E., Robinson, B. A., & Dachs, G. U. (2019) · Hypoxia · doi:10.2147/hp.s201643 · Cited by 32 · see citing works
Factor‐inhibiting HIF‐1 (FIH‐1) is required for human vascular endothelial cell survival
Kiriakidis, S., Henze, A., Kruszynska‐Ziaja, I., Skobridis, K., Theodorou, V., Paleolog, E. M., & Mazzone, M. (2015) · The FASEB Journal · doi:10.1096/fj.14-252379 · Cited by 31 · see citing works
Self-citationWang, C., Li, Y., Chu, C., Zhang, X.-M., Ma, J., Huang, H., Wang, Y.-N., Hong, T., Zhang, J., Pan, X., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.011 · Cited by 26 · see citing works
The roles and signaling pathways of prolyl-4-hydroxylase 2 in the tumor microenvironment
Li, A., Zhang, Y., Wang, Z., Dong, H., Fu, N., & Han, X. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.02.019 · Cited by 24 · see citing works
No Time to Die: How Kidney Cancer Evades Cell Death
Ganini, C., Montanaro, M., Scimeca, M., Palmieri, G., Anemona, L., Concetti, L., Melino, G., Bove, P., Amelio, I., Candi, E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116198 · Cited by 24 · see citing works
Regulation of the hypoxic tumor environment in hepatocellular carcinoma using RNA interference
Choi, S. H., & Park, J. Y. (2017) · Cancer Cell International · doi:10.1186/s12935-016-0374-6 · Cited by 20 · see citing works
Various forms of HIF ‐1α protein characterize the clear cell renal cell carcinoma cell lines
Swiatek, M., Jancewicz, I., Kluebsoongnoen, J., Zub, R., Maassen, A., Kubala, S., Udomkit, A., SIEDLECKI, J. A., Sarnowski, T. J., & Sarnowska, E. A. (2020) · IUBMB Life · doi:10.1002/iub.2281 · Cited by 19 · see citing works
Liao, H., Wang, G.-P., Gu, L., Huang, S., Chen, X., Li, Y., & Cai, S. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.2.473 · Cited by 17 · see citing works
Factor-inhibiting HIF (FIH) promotes lung cancer progression
Río, A. G.-D., Prieto‐Fernández, E., Egia‐Mendikute, L., Antoñana-Vildosola, A., Jiménez-Lasheras, B., Lee, S. Y., Barreira-Manrique, A., Zanetti, S. R., de Blas, A., Velasco-Beltrán, P., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.167394 · Cited by 14 · see citing works
Genetic modification of hypoxia signaling in animal models and its effect on cancer
García-Heredia, J. M., Felipe‐Abrio, B., Cano, D. A., & Carnero, A. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1236-0 · Cited by 14 · see citing works
Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment
Ma, J., Moussawi, K. A., Lou, H., Chan, H. F., Wang, Y., Chadwick, J., Phetsouphanh, C., Slee, E. A., Zhong, S., Leissing, T. M., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2309957121 · Cited by 12 · see citing works
Zakaria, S., Elsebaey, S., Allam, S., & El‐Sisi, A. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113562 · Cited by 11 · see citing works
hZIP1 Inhibits Progression of Clear Cell Renal Cell Carcinoma by Suppressing NF-kB/HIF-1α Pathway
Zhan, B., Dong, X., Yuan, Y., Gong, Z., & Li, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759818 · Cited by 7 · see citing works
Liu, W., He, J., Li, Z., Weng, S., Guo, C.-J., & He, J. (2023) · Viruses · doi:10.3390/v15081644 · Cited by 7 · see citing works
Jensen, C. C., & Warfel, N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00039-6 · Cited by 5 · see citing works
HIF Pathways in Clear Cell Renal Cancer
Lombardi, O., & Mole, D. R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96539 · Cited by 4 · see citing works
Zakaria, S., Elsebaey, S., Allam, S., Abdo, W., & El‐Sisi, A. E. (2023) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892818666230116142606 · Cited by 4 · see citing works
Crosstalk of proteins, miRNAs involved in metastatic and epithelial–mesenchymal transition pathways
Mishra, S., Tripathi, R., & Singh, S. (2016) · Frontiers in Life Science · doi:10.1080/21553769.2016.1256843 · Cited by 2 · see citing works
Janke, K. (2013) · DuEPublico (University of Duisburg-Essen)
Montalto, G., Carroccio, A., Soresi, M., Marco, C. D., Averna, M. R., & Notarbartolo, A. (1991) · PubMed
Najafipour, R., Rakhshani, N., Vakil, L., Zamani, F., Morakabati, A., & Javadi, A. (2016) · DOAJ (DOAJ: Directory of Open Access Journals)
- Authors
- Khan, M. N., Bhattacharyya, T., Andrikopoulos, P., Esteban, M. A., Barod, R., Connor, T., Ashcroft, M., Maxwell, P. H., & Kiriakidis, S.
- Affiliations
- University College London (GB)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Maxwell, P H
- Venue
- British Journal of Cancer
- Published
- 2011-03
- Volume
- 104
- Issue
- 7
- Pages
- 1151-1159
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC3068507
- OpenAlex
- W2030204259
- Cited by
- 40
- References
- 43
- Citations by year
- 2024: 1 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 4 · 2014: 6 · 2013: 2 · 2012: 2
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by-nc-sa)
- UCL Discovery (University College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc-sa)
- Apollo
- Funders
- National Institute for Health and Care Research (NF-SI-0507-10315)
- British Heart Foundation
- European Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- FIH-1, HIF-1α, HIF-2α, clear cell renal cell carcinoma, VHL inactivation, apoptosis, tumor cell survival, HIF target genes, tumour suppressor
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Amino Acids, Dicarboxylic, Cell Survival, Humans, Mixed Function Oxygenases, Kidney Neoplasms, Repressor Proteins, Apoptosis, Cytoprotection, Cell Line, Tumor, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
